nodes	percent_of_prediction	percent_of_DWPC	metapath
Diphenoxylate—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0405	0.0425	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.0315	0.033	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.03	0.0315	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.0233	0.0245	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0226	0.0238	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.0213	0.0223	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0211	0.0221	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0191	0.02	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.0172	0.0181	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.0168	0.0176	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0161	0.0169	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.0158	0.0165	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0156	0.0164	CbGpPWpGaD
Diphenoxylate—OPRM1—nerve—acquired immunodeficiency syndrome	0.0153	0.327	CbGeAlD
Diphenoxylate—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.0146	0.0153	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0141	0.0148	CbGpPWpGaD
Diphenoxylate—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.0138	0.0144	CbGpPWpGaD
Diphenoxylate—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.0138	0.0144	CbGpPWpGaD
Diphenoxylate—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.0134	0.0141	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.0128	0.0134	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.0128	0.0134	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0119	0.0125	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.0118	0.0124	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.0116	0.0121	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.0108	0.0113	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.0106	0.0112	CbGpPWpGaD
Diphenoxylate—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.0101	0.0106	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.01	0.0105	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.01	0.0105	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00973	0.0102	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00947	0.00994	CbGpPWpGaD
Diphenoxylate—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.00924	0.0097	CbGpPWpGaD
Diphenoxylate—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00898	0.00942	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.0088	0.00924	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00873	0.00915	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00857	0.00899	CbGpPWpGaD
Diphenoxylate—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00845	0.00886	CbGpPWpGaD
Diphenoxylate—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00845	0.00886	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00834	0.00875	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00825	0.00865	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.0079	0.00829	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00789	0.00828	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00784	0.00822	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00762	0.00799	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00742	0.00778	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00742	0.00778	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00721	0.00757	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00714	0.00749	CbGpPWpGaD
Diphenoxylate—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00686	0.0072	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00671	0.00704	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00671	0.00704	CbGpPWpGaD
Diphenoxylate—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00666	0.00698	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00652	0.00684	CbGpPWpGaD
Diphenoxylate—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00643	0.00674	CbGpPWpGaD
Diphenoxylate—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00626	0.00657	CbGpPWpGaD
Diphenoxylate—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00626	0.00657	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00618	0.00648	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00611	0.00641	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00601	0.00631	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00585	0.00614	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00581	0.00609	CbGpPWpGaD
Diphenoxylate—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.00581	0.00609	CbGpPWpGaD
Diphenoxylate—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00579	0.00607	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00564	0.00592	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00544	0.00571	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00537	0.00564	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00529	0.00555	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00511	0.00536	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00511	0.00536	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00511	0.00536	CbGpPWpGaD
Diphenoxylate—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00508	0.00533	CbGpPWpGaD
Diphenoxylate—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00505	0.108	CbGeAlD
Diphenoxylate—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.005	0.00524	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00498	0.00522	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00498	0.00522	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00487	0.00511	CbGpPWpGaD
Diphenoxylate—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00487	0.104	CbGeAlD
Diphenoxylate—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00476	0.005	CbGpPWpGaD
Diphenoxylate—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.0046	0.00483	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00452	0.00474	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00446	0.00468	CbGpPWpGaD
Diphenoxylate—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00429	0.0045	CbGpPWpGaD
Diphenoxylate—OPRM1—blood—acquired immunodeficiency syndrome	0.00425	0.0907	CbGeAlD
Diphenoxylate—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.00409	0.0873	CbGeAlD
Diphenoxylate—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00403	0.00423	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00398	0.00418	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00389	0.00408	CbGpPWpGaD
Diphenoxylate—OPRD1—brain—acquired immunodeficiency syndrome	0.00386	0.0825	CbGeAlD
Diphenoxylate—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00379	0.00398	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00379	0.00398	CbGpPWpGaD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00379	0.00397	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.0037	0.00388	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00361	0.00379	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.0035	0.00368	CbGpPWpGaD
Diphenoxylate—OPRM1—nervous system—acquired immunodeficiency syndrome	0.00345	0.0736	CbGeAlD
Diphenoxylate—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00341	0.00358	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00335	0.00351	CbGpPWpGaD
Diphenoxylate—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.00332	0.0709	CbGeAlD
Diphenoxylate—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.00314	0.00329	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00309	0.00324	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00307	0.00322	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00295	0.0031	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00295	0.0031	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00289	0.00303	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00289	0.00303	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00288	0.00302	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00279	0.00293	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00267	0.0028	CbGpPWpGaD
Diphenoxylate—OPRM1—brain—acquired immunodeficiency syndrome	0.00263	0.0563	CbGeAlD
Diphenoxylate—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00262	0.00275	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00262	0.00275	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.0026	0.00272	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00229	0.0024	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00228	0.00239	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.0022	0.00231	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00219	0.00229	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00219	0.00229	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00217	0.00227	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00214	0.00225	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00214	0.00225	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00207	0.00217	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.002	0.00209	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00198	0.00208	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00198	0.00207	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00197	0.00206	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00194	0.00204	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00194	0.00204	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00182	0.00191	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.0018	0.00189	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00165	0.00173	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00163	0.00171	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.0016	0.00168	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00155	0.00163	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00155	0.00163	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00148	0.00155	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00147	0.00154	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00146	0.00153	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00135	0.00142	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00133	0.0014	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00122	0.00128	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00118	0.00124	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.00116	0.00122	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00115	0.00121	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00115	0.00121	CbGpPWpGaD
Diphenoxylate—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00114	0.0012	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.00106	0.00111	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.00104	0.00109	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000874	0.000917	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000861	0.000903	CbGpPWpGaD
Diphenoxylate—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000848	0.00089	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000787	0.000826	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.00077	0.000808	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000614	0.000644	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000611	0.000641	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000455	0.000477	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000453	0.000475	CbGpPWpGaD
Diphenoxylate—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000361	0.000379	CbGpPWpGaD
Diphenoxylate—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000267	0.000281	CbGpPWpGaD
